Literature DB >> 19402065

Prognostic factors for survival in metastatic renal cell carcinoma: update 2008.

Ronald M Bukowski1.   

Abstract

A variety of prognostic factor models to predict survival in patients with metastatic renal cell carcinoma have been developed. Diverse populations of patients with variable treatments have been used for these analyses. A variety of clinical, pathologic, and molecular factors have been studied, but current models use predominantly easily obtained clinical factors. These approaches are reviewed, and current approaches to further refine and develop these techniques are reviewed. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19402065     DOI: 10.1002/cncr.24226

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.

Authors:  Chiara Grisanzio; Apryle Seeley; Michelle Chang; Michael Collins; Arianna Di Napoli; Su-Chun Cheng; Andrew Percy; Rameen Beroukhim; Sabina Signoretti
Journal:  J Pathol       Date:  2011-06-27       Impact factor: 7.996

2.  Docosahexaenoic acid inhibits the phosphorylation of STAT3 and the growth and invasion of renal cancer cells.

Authors:  Shinsuke Tasaki; Akio Horiguchi; Takako Asano; Keiichi Ito; Tomohiko Asano; Hirotaka Asakura
Journal:  Exp Ther Med       Date:  2017-06-15       Impact factor: 2.447

3.  Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein.

Authors:  S P K Jagdev; W Gregory; N S Vasudev; P Harnden; S Sim; D Thompson; J Cartledge; P J Selby; R E Banks
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

4.  Preoperative serum docosahexaenoic acid level predicts prognosis of renal cell carcinoma.

Authors:  Shinsuke Tasaki; Akio Horiguchi; Takako Asano; Kenji Kuroda; Akinori Sato; Junichi Asakuma; Keiichi Ito; Tomohiko Asano; Hirotaka Asakura
Journal:  Mol Clin Oncol       Date:  2016-05-09

5.  Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.

Authors:  Gan Yu; Weimin Yao; Kiranmai Gumireddy; Anping Li; Ji Wang; Wei Xiao; Ke Chen; Haibing Xiao; Heng Li; Kun Tang; Zhangqun Ye; Qihong Huang; Hua Xu
Journal:  Mol Cancer Ther       Date:  2014-09-23       Impact factor: 6.261

6.  The role of neutrophil-lymphocyte ratio as a prognostic indicator in patients undergoing nephrectomy for renal cell carcinoma.

Authors:  Nathan Grimes; Cathal Hannan; Matthew Tyson; Ali Thwaini
Journal:  Can Urol Assoc J       Date:  2018-03-19       Impact factor: 1.862

7.  Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients.

Authors:  Ana L Teixeira; Marta Ferreira; Joana Silva; Mónica Gomes; Francisca Dias; Juliana I Santos; Joaquina Maurício; Francisco Lobo; Rui Medeiros
Journal:  Tumour Biol       Date:  2013-12-31

8.  Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy.

Authors:  Ondrej Slaby; Jana Jancovicova; Radek Lakomy; Marek Svoboda; Alexandr Poprach; Pavel Fabian; Leos Kren; Jaroslav Michalek; Rostislav Vyzula
Journal:  J Exp Clin Cancer Res       Date:  2010-07-07

9.  PGE2 promotes renal carcinoma cell invasion through activated RalA.

Authors:  Z Li; Y Zhang; W J Kim; Y Daaka
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

10.  Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.

Authors:  Saadia A Aziz; Joshua A Sznol; Adebowale Adeniran; Fabio Parisi; Yuval Kluger; Robert L Camp; Harriet M Kluger
Journal:  BMC Clin Pathol       Date:  2013-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.